ClinicalTrials.gg
CompletedNCT00514852Updated Dec 15, 2009Results posted

Safety and Efficacy of an Artificial Tear for the Treatment of Dry Eye

An interventional study of Carboxymethylcellulose and Glycerin based artificial tear and Carboxymethylcellulose in Dry Eye Syndrome, sponsored by Allergan. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2009-12-15.

Sponsored by Allergan (part of AbbVie) · Not applicable, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
316
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 48 studies in Dry Eye Syndromes by AbbVie — 1 open to participants now, 1 under way, none of them phase 3. Dry Eye Syndromes · AbbVie.

Enrollment
3rd of 40
316 · median 80
Started
2007
with 3 others
No phase
11 of 48
none open now
Registered
3rd of 48
by date

Among the 48 studies in Dry Eye Syndromes by AbbVie, this one is the 3rd largest by enrollment of the 40 interventional ones that give a count, is one of 4 that started in 2007, is one of 11 with no phase, and was the 3rd registered.

Dry Eye Syndromes

1,369 studies on the registry are indexed under Dry Eye Syndromes; 208 are open to participants now.

Browse Dry Eye Syndromes studies →

Open to participants now

1 of the 48 studies in Dry Eye Syndromes by AbbVie is open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 48 studies in Dry Eye Syndromes by AbbVie, or all of them as a file.
02

Study summary

The efficacy, safety and acceptability of a new artificial tear in subjects with dry eye will be compared to a currently-available artificial tear

03

Conditions studied

  • Dry Eye Syndrome

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Mild, moderate or Severe Symptoms of Dry Eye

Exclusion criteria

Exclusion Criteria:

  • Uncontrolled systemic disease
  • Use of systemic medications affecting dry eye
  • Pregnancy or planning a pregnancy
  • Contact lens wear
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
316 participants (actual)

Study arms

  • Experimental
    1

    Carboxymethylcellulose and Glycerin based artificial tear

    Drug: Carboxymethylcellulose and Glycerin based artificial tear

  • Active comparator
    2

    Carboxymethylcellulose

    Drug: Carboxymethylcellulose

Interventions

  • DrugCarboxymethylcellulose and Glycerin based artificial tear

    1 to 2 drops into each eye as needed but at least twice daily

  • 1 to 2 drops into each eye as needed but at least twice daily

    Also known as: Refresh Plus

06

What researchers measure

Primary outcomes

  1. Change From Baseline at Day 30 in Ocular Surface Disease Index© Questionnaire Score

    Ocular Surface Disease Index© Questionnaire Score is measured on 12 domains; a 5-point scale (0-4) for each domain. Sum of the domain scores is normalized to a severity scale of 0-100 (0 = no symptoms, 100 = maximum severity)

    Time frame: Change from baseline at Day 30

Secondary outcomes

  1. Change From Baseline at Day 30 in Schirmer Test, With Anesthesia

    Schirmer Test measures the rate of the secretion of tears

    Time frame: Change from baseline at Day 30

  2. Change From Baseline at Day 30 in Tear Break-Up Time, With Fluorescein

    Measures the stability of tear film. The average of 3 measures.

    Time frame: Change from baseline at Day 30

  3. Patient Acceptability Score (Dryness) at Day 30

    Dryness Severity Visual Analog Scale is measured on a 0-100 point scale (0 = could not be worse, 100 = none at all).

    Time frame: Day 30

  4. Patient Acceptability Score (Vision) at Day 30

    Vision Quality Visual Analog Scale is measured on a 0-100 point scale (0 = very poor, has never been worse, 100 = excellent, has never been better).

    Time frame: Day 30

  5. Change From Baseline at Day 30 in Ocular Surface (Corneal) Staining With Fluorescein

    Sum of corneal staining over 5 zones; each zone was measured on a modified Oxford Scheme of 0-5 (0=no staining, 5=most severe staining), with total score from 0-25 (0= no staining, 25 = most severe staining)

    Time frame: Change from baseline at Day 30

  6. Change From Baseline at Day 30 in Ocular Surface (Conjunctival) Staining With Fluorescein

    Sum of conjunctival staining over 6 zones; each zone was measured on a modified Oxford Scheme of 0-5 (0=no staining, 5=most severe staining), with total score from 0-30 (0=no staining, 30=most severe staining)

    Time frame: Change from baseline at Day 30

  7. Change From Baseline at Day 30 in Subjective Evaluation of Symptom of Dryness Score

    Measures dry eye severity on a scale of 0-4 (0 = none, 4 = severe)

    Time frame: Change from baseline at Day 30

07

Results

Posted Dec 15, 2009

Participant flow

Participant flow — Overall Study
MilestoneCarboxymethylcellulose and Glycerin Based Artificial TearCarboxymethylcellulose Based Artificial Tear
Started157159
Completed152154
Not completed55

Outcome measures

PrimaryChange From Baseline at Day 30 in Ocular Surface Disease Index© Questionnaire Score

Ocular Surface Disease Index© Questionnaire Score is measured on 12 domains; a 5-point scale (0-4) for each domain. Sum of the domain scores is normalized to a severity scale of 0-100 (0 = no symptoms, 100 = maximum severity)

Time frame:
Change from baseline at Day 30
Reported as:
Mean · Units on a scale
Change From Baseline at Day 30 in Ocular Surface Disease Index© Questionnaire Score
Units on a scaleCarboxymethylcellulose and Glycerin Based Artificial TearCarboxymethylcellulose Based Artificial Tear
Day 1 (Baseline)44 ± 18.145.2 ± 18.3
Day 7-12.6 ± 14.9-13.6 ± 17.8
Day 30-16.3 ± 16.4-16.6 ± 20.3
SecondaryChange From Baseline at Day 30 in Schirmer Test, With Anesthesia

Schirmer Test measures the rate of the secretion of tears

Time frame:
Change from baseline at Day 30
Reported as:
Mean · mm/5min
Change From Baseline at Day 30 in Schirmer Test, With Anesthesia
mm/5minCarboxymethylcellulose and Glycerin Based Artificial TearCarboxymethylcellulose Based Artificial Tear
Day 1 (Baseline)9.2 ± 7.28.6 ± 6.8
Day 71.2 ± 5.11.2 ± 5.6
Day 301.7 ± 6.91.8 ± 7.3
SecondaryChange From Baseline at Day 30 in Tear Break-Up Time, With Fluorescein

Measures the stability of tear film. The average of 3 measures.

Time frame:
Change from baseline at Day 30
Reported as:
Mean · seconds
Change From Baseline at Day 30 in Tear Break-Up Time, With Fluorescein
secondsCarboxymethylcellulose and Glycerin Based Artificial TearCarboxymethylcellulose Based Artificial Tear
Day 1 (Baseline)4.3 ± 2.14.3 ± 2.0
Day 70.9 ± 2.30.9 ± 2.1
Day 301.1 ± 2.70.9 ± 2.4
SecondaryPatient Acceptability Score (Dryness) at Day 30

Dryness Severity Visual Analog Scale is measured on a 0-100 point scale (0 = could not be worse, 100 = none at all).

Time frame:
Day 30
Reported as:
Mean · Units on scale
Patient Acceptability Score (Dryness) at Day 30
Units on scaleCarboxymethylcellulose and Glycerin Based Artificial TearCarboxymethylcellulose Based Artificial Tear
Day 1 (Baseline)47.4 ± 22.844.6 ± 20.5
Day 760.7 ± 21.157.7 ± 22.5
Day 3063.3 ± 22.763.8 ± 22.8
SecondaryPatient Acceptability Score (Vision) at Day 30

Vision Quality Visual Analog Scale is measured on a 0-100 point scale (0 = very poor, has never been worse, 100 = excellent, has never been better).

Time frame:
Day 30
Reported as:
Mean · Units on a scale
Patient Acceptability Score (Vision) at Day 30
Units on a scaleCarboxymethylcellulose and Glycerin Based Artificial TearCarboxymethylcellulose Based Artificial Tear
Day 1 (Baseline)56.8 ± 22.454.2 ± 21.6
Day 765.3 ± 17.862.6 ± 19.6
Day 3065.4 ± 20.166.4 ± 19.4
Post-hocVision Subscale of the Ocular Surface Disease Index Questionnaire© at Day 30

Vision subscale of the Ocular Surface Disease Index Questionnaire© is measured on 6 domains; a 5-point scale (0-4) for each domain. Sum of the domain scores is normalized to a severity scale of 0-100 (0 = no symptoms, 100 = maximum severity)

Time frame:
Day 30
Reported as:
Mean · Units on a scale
Vision Subscale of the Ocular Surface Disease Index Questionnaire© at Day 30
Units on a scaleCarboxymethylcellulose and Glycerin Based Artificial TearCarboxymethylcellulose Based Artificial Tear
Day 1 (Baseline)37.6 ± 21.541.6 ± 21.6
Day 724.8 ± 20.026.9 ± 20.2
Day 3022.8 ± 20.425.6 ± 22.4
Post-hocOcular Surface Staining With Fluorescein (Central Cornea) at Day 30

Central staining score is based on modified Oxford Scheme measured on a scale of 0-5 (0= no staining, 5= most severe staining)

Time frame:
Day 30
Reported as:
Mean · Units on a scale
Ocular Surface Staining With Fluorescein (Central Cornea) at Day 30
Units on a scaleCarboxymethylcellulose and Glycerin Based Artificial TearCarboxymethylcellulose Based Artificial Tear
Day 1 (Baseline)0.7 ± 0.80.8 ± 0.8
Day 70.5 ± 0.70.5 ± 0.7
Day 300.4 ± 0.60.4 ± 0.7
SecondaryChange From Baseline at Day 30 in Ocular Surface (Corneal) Staining With Fluorescein

Sum of corneal staining over 5 zones; each zone was measured on a modified Oxford Scheme of 0-5 (0=no staining, 5=most severe staining), with total score from 0-25 (0= no staining, 25 = most severe staining)

Time frame:
Change from baseline at Day 30
Reported as:
Mean · Units on a scale
Change From Baseline at Day 30 in Ocular Surface (Corneal) Staining With Fluorescein
Units on a scaleCarboxymethylcellulose and Glycerin Based Artificial TearCarboxymethylcellulose Based Artificial Tear
Day 1 (Baseline)4.0 ± 3.34.4 ± 3.4
Day 7-1.2 ± 2.3-0.9 ± 2.4
Day 30-1.3 ± 2.4-1.5 ± 2.5
SecondaryChange From Baseline at Day 30 in Ocular Surface (Conjunctival) Staining With Fluorescein

Sum of conjunctival staining over 6 zones; each zone was measured on a modified Oxford Scheme of 0-5 (0=no staining, 5=most severe staining), with total score from 0-30 (0=no staining, 30=most severe staining)

Time frame:
Change from baseline at Day 30
Reported as:
Mean · Units on a scale
Change From Baseline at Day 30 in Ocular Surface (Conjunctival) Staining With Fluorescein
Units on a scaleCarboxymethylcellulose and Glycerin Based Artificial TearCarboxymethylcellulose Based Artificial Tear
Day 1 (Baseline)4.9 ± 4.45.1 ± 5.0
Day 7-1.1 ± 3.1-1.0 ± 3.2
Day 30-1.7 ± 3.3-1.5 ± 2.8
SecondaryChange From Baseline at Day 30 in Subjective Evaluation of Symptom of Dryness Score

Measures dry eye severity on a scale of 0-4 (0 = none, 4 = severe)

Time frame:
Change from baseline at Day 30
Reported as:
Mean · Units on a scale
Change From Baseline at Day 30 in Subjective Evaluation of Symptom of Dryness Score
Units on a scaleCarboxymethylcellulose and Glycerin Based Artificial TearCarboxymethylcellulose Based Artificial Tear
Day 1 (Baseline)2.8 ± 0.72.8 ± 0.8
Day 7-0.5 ± 0.8-0.5 ± 0.8
Day 30-0.7 ± 1.0-0.7 ± 0.9

Adverse events

Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Carboxymethylcellulose and Glycerin Based Artificial Tear—1/157 (0.6%)0/157 (0%)
Carboxymethylcellulose Based Artificial Tear—1/159 (0.6%)0/159 (0%)
Most frequent serious events
Most frequent serious events
EventCarboxymethylcellulose and Glycerin Based Artificial TearCarboxymethylcellulose Based Artificial Tear
Transient Ischaemic AttackNervous system disorders1/1570/159
MenorrhagiaReproductive system and breast disorders0/1571/159

Baseline characteristics

Age, Customized
Age, Customized(participants)Carboxymethylcellulose and Glycerin Based Artificial TearCarboxymethylcellulose Based Artificial TearTotal
<40 years181533
>=40 years139144283
Sex: Female, Male
Sex: Female, Male(Participants)Carboxymethylcellulose and Glycerin Based Artificial TearCarboxymethylcellulose Based Artificial TearTotal
Female120125245
Male373471
08

Study locations

1 site
  • San Diego, California, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2007, a primary completion of Jan 2008 and a completion of Jan 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2009, 1 year 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 8, 2007
First posted
Aug 10, 2007
Start
Oct 2007
Primary completionActual
Jan 2008
CompletionActual
Jan 2008
Results first posted
Dec 15, 2009
Last update
Dec 15, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 15, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00514852
Lead sponsor
Allergan
First posted
Aug 10, 2007
Start date
Oct 2007
Primary completion
Jan 2008
Completion
Jan 2008
Results posted
Dec 15, 2009
Last update
Dec 15, 2009

Study contacts

Medical Director
study director · Allergan

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion